Wednesday, September 18, 2013
• Celtaxsys Inc., of Atlanta, said it completed the first two trials in its Phase I program testing lead candidate CTX-4430, a small-molecule inhibitor of leukotriene A4 hydrolase in development for treating cystic fibrosis (CF) lung disease.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.